<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00113646</url>
  </required_header>
  <id_info>
    <org_study_id>02-163</org_study_id>
    <nct_id>NCT00113646</nct_id>
  </id_info>
  <brief_title>Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies</brief_title>
  <official_title>Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if recipients of non-myeloablative ex-vivo T-cell&#xD;
      depleted peripheral blood (PBSC) stem cell transplantation using a mismatched related donor&#xD;
      will have less severe graft versus host disease (GVHD), transplant related mortality, and&#xD;
      less graft failure compared to alternative haploidentical stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One major obstacle to further advancement in the role of bone marrow transplant (BMT) in&#xD;
      hematological malignancies is graft-versus-host-disease (GVHD), which can best be prevented&#xD;
      by removing T-cells from the donor stem cell product. However, previous experience with&#xD;
      T-cell depletion has been associated with an increased rate of engraftment failure and&#xD;
      leukemic relapse. Another obstacle is that a large fraction of leukemia and lymphomas afflict&#xD;
      older patients who are more prone to GVHD and have co-morbid conditions that prevent them&#xD;
      from being a candidate for BMT.&#xD;
&#xD;
      This trial uses a non-myeloablative conditioning regimen with cyclophosphamide, MEDI-507,&#xD;
      fludarabine, and thymic irradiation followed by a T-cell depleted PBSC infusion. Cyclosporine&#xD;
      is used for GVHD prophylaxis, and tapered beginning on day 35. Data from our mouse model and&#xD;
      previous clinical trials have demonstrated that this approach can induce mixed chimerism&#xD;
      without GVHD, with the potential for conversion of mixed chimerism to full donor&#xD;
      hematopoiesis following donor leukocyte infusions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Expiration of MEDI-507&#xD;
  </why_stopped>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the risk of graft loss and severe GVHD or transplant related mortality at &lt; 100 days following HLA-mismatched non-myeloablative stem cell transplantation.</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate progression free and overall survival following HLA mismatched non-myeloablative stem cell transplantation for hematologic malignancy.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
    <description>MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant</intervention_name>
    <description>Cyclophosphamide 60 mg/kg on transplant days -7 and -6; Fludarabine 25 mg/m2 days -5,-4,-3,-2,-1; MEDI-507 0.1 mg/kg on day -8, 0.6 mg/kg on days -7,-6</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease Status: NHL, HD, MM that are chemorefractory or relapsed; CLL that is Rai&#xD;
             stage III or IV, or lymphocyte doubling time of 6 months, or stage I/II resistant to &gt;&#xD;
             2 cycles of chemotherapy regimens; CML in accelerated or blast phase; MDS with&#xD;
             life-threatening cytopenias; patients who have had a previous autologous or allogeneic&#xD;
             bone marrow or stem cell transplant; other hematological disorders where allogeneic&#xD;
             transplant is appropriate and the risk of conventional transplantation is considered&#xD;
             to be unacceptably high.&#xD;
&#xD;
          -  estimated disease free survival of less than one year&#xD;
&#xD;
          -  ECOG performance status of 0, 1, or 2&#xD;
&#xD;
          -  HLA 1 to 3 mismatched (at A, B, DR loci) related donor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac disease: symptomatic congestive heart failure, ejection fraction of &lt; 45%,&#xD;
             active angina pectoris or uncontrolled hypertension.&#xD;
&#xD;
          -  Pulmonary disease: severe chronic obstructive lung disease, or symptomatic restrictive&#xD;
             lung disease, or corrected DLCO of &lt; 50%&#xD;
&#xD;
          -  Renal disease: serum creatinine &gt; 2.0 mg/dl or creatinine clearance &lt; 50 ml/min&#xD;
&#xD;
          -  Hepatic disease: serum bilirubin &gt; 2.0 mg/dl or alkaline phosphate, SGPT or SGOT &gt; 3 x&#xD;
             normal&#xD;
&#xD;
          -  Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other&#xD;
             neuropsychiatric abnormalities believed to preclude transplantation&#xD;
&#xD;
          -  HIV antibody or Hepatitis B surface antigen positivity&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Presence of HAMA or HAHA in patient previously treated with monoclonal antibody&#xD;
             therapy or who have received a product in which the preparation involved a monoclonal&#xD;
             antibody affinity step&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Spitzer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital, Harvard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>June 9, 2005</study_first_submitted>
  <study_first_submitted_qc>June 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2005</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Thomas Spitzer</investigator_full_name>
    <investigator_title>Director Cellular Therapy and Transplantation Laboratory</investigator_title>
  </responsible_party>
  <keyword>Non-Myeloablative</keyword>
  <keyword>T-cell Depleted</keyword>
  <keyword>Mismatched</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

